Adva Levy‐Barda

This paper develops and tests Anti-4CB1, an anti-HVEM monoclonal antibody, showing enhanced anti-tumor activity in vitro and in vivo, particularly when combined with Anti-PD1, and correlates HVEM expression with treatment response.

This study examines how JAK inhibition affects inflammatory responses differently in colonic versus ileal mucosa from IBD patients and controls, finding site-specific effects and gene expression changes.

This paper develops a validated protocol for using Oxford Nanopore methylation sequencing on FFPE samples to classify brain tumors, enabling point-of-care diagnosis.

This study analyzes plasma proteomic changes in NSCLC patients on immunotherapy to identify biomarkers of treatment response and resistance.